The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...

Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

The Trump administration has withdrawn a plan to ban menthol cigarettes in the U.S., in a setback to health regulators and ...

In this week’s edition of InnovationRx, we look at HHS nominee Robert F. Kennedy Jr.’s first Senate confirmation hearing, the ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

At AcceleDev, Dr. Kang will oversee operations at the company's state-of-the-art facility in Cranbury, New Jersey, guide the expansion of U.S. and China-based operations, and spearhead innovative ...

A partnership between Eisai ... effort by the pharma group to develop an ‘ecosystem’ to support patients. The alliance, first formed in 2022, envisages a series of insurance products ...

IV Maintenance Dosing for the treatment of Early Alzheimer's Disease Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease ...